GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » Cyclically Adjusted FCF per Share

Scinopharm Taiwan (TPE:1789) Cyclically Adjusted FCF per Share : NT$0.93 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Scinopharm Taiwan's adjusted free cash flow per share for the three months ended in Mar. 2025 was NT$0.094. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$0.93 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Scinopharm Taiwan's average Cyclically Adjusted FCF Growth Rate was 12.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Scinopharm Taiwan was 12.00% per year. The lowest was 7.20% per year. And the median was 9.60% per year.

As of today (2025-05-28), Scinopharm Taiwan's current stock price is NT$17.35. Scinopharm Taiwan's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was NT$0.93. Scinopharm Taiwan's Cyclically Adjusted Price-to-FCF of today is 18.66.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Scinopharm Taiwan was 57.57. The lowest was 19.14. And the median was 36.39.


Scinopharm Taiwan Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Scinopharm Taiwan's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan Cyclically Adjusted FCF per Share Chart

Scinopharm Taiwan Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 0.64 0.73 0.80 0.90

Scinopharm Taiwan Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.93 0.96 0.90 0.93

Competitive Comparison of Scinopharm Taiwan's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's Cyclically Adjusted Price-to-FCF falls into.


;
;

Scinopharm Taiwan Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Scinopharm Taiwan's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.094/134.9266*134.9266
=0.094

Current CPI (Mar. 2025) = 134.9266.

Scinopharm Taiwan Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.343 100.684 0.460
201509 -0.086 100.392 -0.116
201512 0.251 99.792 0.339
201603 0.502 100.470 0.674
201606 0.069 101.688 0.092
201609 0.316 101.861 0.419
201612 0.634 101.863 0.840
201703 0.127 102.862 0.167
201706 -0.094 103.349 -0.123
201709 0.486 104.136 0.630
201712 0.202 104.011 0.262
201803 0.324 105.290 0.415
201806 0.057 106.317 0.072
201809 0.579 106.507 0.733
201812 0.409 105.998 0.521
201903 0.489 107.251 0.615
201906 0.009 108.070 0.011
201909 0.214 108.329 0.267
201912 0.148 108.420 0.184
202003 0.291 108.902 0.361
202006 0.069 108.767 0.086
202009 0.270 109.815 0.332
202012 0.341 109.897 0.419
202103 0.038 111.754 0.046
202106 0.011 114.631 0.013
202109 0.069 115.734 0.080
202112 0.111 117.630 0.127
202203 0.073 121.301 0.081
202206 0.228 125.017 0.246
202209 0.340 125.227 0.366
202212 0.030 125.222 0.032
202303 0.165 127.348 0.175
202306 -0.273 128.729 -0.286
202309 0.073 129.860 0.076
202312 -0.022 129.419 -0.023
202403 0.376 131.776 0.385
202406 -0.008 132.554 -0.008
202409 -0.033 133.029 -0.033
202412 0.260 133.157 0.263
202503 0.094 134.927 0.094

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Scinopharm Taiwan  (TPE:1789) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Scinopharm Taiwan's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=17.35/0.93
=18.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Scinopharm Taiwan was 57.57. The lowest was 19.14. And the median was 36.39.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Scinopharm Taiwan Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinopharm Taiwan Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.

Scinopharm Taiwan Headlines

No Headlines